Epidemiology, treatment and prevention of healthcare-associated urinary tract infections

Basit Öğe Kaydı
dc.authoridbjerklund johansen, truls erik/0000-0003-3490-6460
dc.authorwosidNaber, Kurt/AAR-9997-2020
dc.authorwosidKiyota, Hiroshi/N-9515-2015
dc.contributor.authorWagenlehner, F. M. E.
dc.contributor.authorCek, Mete
dc.contributor.authorNaber, Kurt G.
dc.contributor.authorKiyota, Hiroshi
dc.contributor.authorBjerklund-Johansen, Truls E.
dc.date.accessioned2024-06-12T11:03:03Z
dc.date.available2024-06-12T11:03:03Z
dc.date.issued2012
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives Healthcare-associated urinary tract infections (HAUTIs) are the most frequent healthcare-associated infections in general hospitals. They are almost exclusively complicated UTIs, although complicating factors are very heterogenous. HAUTIs are mainly catheter associated. Most of them are asymptomatic and do not need antimicrobial therapy. However, cross-contamination and cross-infection may contribute to distribution of resistant uropathogens. The bacterial spectrum of HAUTI is broad, and antibiotic resistance is common. Methods The authors reviewed the literature from 2000 to 2010 to determine the epidemiology, prevention and best treatment strategies for HAUTI. The recommendations were summarized by determining the level of evidence and grading each recommendation. Results The treatment for HAUTI encompasses treatment for complicating factors as well as antimicrobial chemotherapy. At least in serious UTI, adequate initial antibiotic therapy results in lower mortality. Therefore, the initial antibiotic regimen must provide sufficient antibiotic coverage. This can only be achieved if the local or regional bacterial spectrum and antibiotic resistance patterns of uropathogens are followed continuously. Provisional microbiological findings, such as reports on Gram-stain or certain biochemical results, can lead to early stratification of pathogens and allow a more tailored empiric antibiotic therapy. Antibiotic therapy of HAUTI has to consider therapeutic success in the individual patient and prevention of emergence of antibiotic-resistant mutants. For both aspects, adequate drug selection and dosing are paramount. Discussion Antibiotic treatment for HAUTI should follow prudent antibiotic use to prevent emergence of antibiotic resistance.en_US
dc.identifier.doi10.1007/s00345-011-0757-1
dc.identifier.endpage67en_US
dc.identifier.issn0724-4983
dc.identifier.issn1433-8726
dc.identifier.issue1en_US
dc.identifier.pmid21898083en_US
dc.identifier.scopus2-s2.0-84856228220en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage59en_US
dc.identifier.urihttps://doi.org/10.1007/s00345-011-0757-1
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21497
dc.identifier.volume30en_US
dc.identifier.wosWOS:000302405800008en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofWorld Journal Of Urologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHealthcare-Associated UTIen_US
dc.subjectNosocomial UTIen_US
dc.subjectAntibiotic Treatment For UTIen_US
dc.subjectEmergence Of Antibiotic-Resistant Uropathogensen_US
dc.subjectAntimicrobial Surveillance Programen_US
dc.subjectHospitalized-Patientsen_US
dc.subjectRisk-Factorsen_US
dc.subjectAsymptomatic Bacteriuriaen_US
dc.subjectEuropean Perspectiveen_US
dc.subjectUrology Departmentsen_US
dc.subjectNorth-Americaen_US
dc.subjectPathogensen_US
dc.subjectSusceptibilityen_US
dc.subjectCathetersen_US
dc.titleEpidemiology, treatment and prevention of healthcare-associated urinary tract infectionsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu